Next Article in Journal
Lipopolysaccharide-Induced Nitric Oxide, Prostaglandin E2, and Cytokine Production of Mouse and Human Macrophages Are Suppressed by Pheophytin-b
Next Article in Special Issue
Sphingosine-1-Phosphate Receptor 1, Expressed in Myeloid Cells, Slows Diet-Induced Atherosclerosis and Protects against Macrophage Apoptosis in Ldlr KO Mice
Previous Article in Journal
Pan-Domain Analysis of ZIP Zinc Transporters
Previous Article in Special Issue
Plasma Sphingolipids in Acute Pancreatitis
Open AccessArticle

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects

1
Department of Clinical Pharmacology, Idorsia Pharmaceuticals Ltd., Allschwil 4123, Switzerland
2
Quintiles Drug Research Unit, London SE1 1YR, UK
3
Simbec Research Ltd., Merthyr Tydfil CF48 4DR, UK
4
Department of Global Drug Safety, Actelion Pharmaceuticals Ltd., Allschwil 4123, Switzerland
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(12), 2636; https://doi.org/10.3390/ijms18122636
Received: 31 October 2017 / Revised: 28 November 2017 / Accepted: 1 December 2017 / Published: 6 December 2017
(This article belongs to the Special Issue Sphingolipids: Signals and Disease)
The pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a potent sphingosine-1-phosphate subtype 1 receptor modulator, were investigated in three sub-studies. Two double-blind, placebo-controlled, randomised studies in healthy male subjects were performed. Cenerimod was administered either as single dose (1, 3, 10 or 25 mg; Study 1) or once daily for 35 days (0.5, 1, 2 or 4 mg; Study 2). A two-period cross-over, open-label study was performed to assess the food effect (1 mg, Study 3). The pharmacokinetic profile of cenerimod was characterised by a tmax of 5.0–6.2 h. Terminal half-life after single and multiple doses ranged from 170 to 199 h and 283 to 539 h, respectively. Food had no relevant effect on the pharmacokinetics of cenerimod. A dose-dependent decrease in lymphocyte count was observed after initiation of cenerimod and reached a plateau (maximum change from baseline: −64%) after 20–23 days of treatment. Lymphocyte counts returned to baseline values at end-of-study examination. One serious adverse event of circulatory collapse (25 mg dose group, maximum tolerated dose: 10 mg) and adverse events of mild-to-moderate intensity were reported. Treatment initiation was associated with transient decreases in heart rate and blood pressure at doses >1 and ≥10 mg, respectively. View Full-Text
Keywords: pharmacokinetics; pharmacodynamics; S1P1 receptor modulator; lymphocyte; tolerability; food effect pharmacokinetics; pharmacodynamics; S1P1 receptor modulator; lymphocyte; tolerability; food effect
Show Figures

Figure 1

MDPI and ACS Style

Juif, P.-E.; Baldoni, D.; Reyes, M.; Wilbraham, D.; Febbraro, S.; Vaclavkova, A.; Hoch, M.; Dingemanse, J. Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects. Int. J. Mol. Sci. 2017, 18, 2636.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop